复必泰(Comirnaty-COVID-19 mRNA vaccine) - 药物靶点：SARS-CoV-2 S protein_在研适应症：新型冠状病毒感染，严重急性呼吸综合征，流感病毒感染_专利_临床

概要

基本信息

药物类型

预防性疫苗、mRNA疫苗

别名

BNT-162b2 Bivalent (WT/OMI BA.4/BA.5)、BNT162b2 Bivalent (WT/OMI BA.1)、Bretovameran

+ [34]

靶点

SARS-CoV-2 S protein

作用方式

调节剂、刺激剂

作用机制

SARS-CoV-2 S protein调节剂(冠状病毒刺突糖蛋白调节剂)、免疫刺激剂

治疗领域

感染呼吸系统疾病其他疾病

在研适应症

新型冠状病毒感染严重急性呼吸综合征流感病毒感染+ [2]

非在研适应症

肺炎球菌感染新冠肺炎后遗症

原研机构

BioNTech SE

在研机构

Pfizer Inc.BioNTech Manufacturing GmbH

BioNTech SE

+ [5]

非在研机构-

权益机构

BioNTech SE

Pfizer Inc.

台湾东洋药品工业股份有限公司

+ [2]

最高研发阶段批准上市

首次获批日期

英国 (2020-12-02),

新型冠状病毒感染

最高研发阶段(中国)无进展

特殊审评紧急使用授权 (中国香港)、附条件批准 (欧盟)、快速通道 (美国)、优先审评 (美国)

登录后查看时间轴

结构/序列

Sequence Code 1234627550

来源: *****

关联

153

项与复必泰相关的临床试验

NCT06743334

/ Not yet recruitingN/A

Secondary Databased Post-marketing Surveillance Study of BNT162b2

This study is to assess the post-marketing safety of BNT162b2 products using nationwide population-based database in Republic of Korea.

开始日期2025-05-28

申办/合作机构

Pfizer Inc.

NCT06919796

/ Not yet recruiting临床2期

Systems Biology of a mRNA Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Given Via Intradermal (ID) Injection Using Tropis Needle-Free Injection System (NFIS) or Intramuscular (IM) Injection Using Needle and Syringe

The purpose of this study is to determine if immune responses differ when the mRNA COVID-19 vaccine is given through different delivery methods, including a needle-free injection system, or via intramuscular injection using needle and syringe

开始日期2025-05-01

申办/合作机构

PharmaJet, Inc.

[+1]

NCT06923137

/ Not yet recruitingN/A

Title Not in Corporate Clinical Trial Registry (CCTR)

The purpose of this study is to learn about how well the yearly updates to the COVID-19 vaccine work in adults (age 18 years and above) with a healthy immune system (the body's cells, tissues and organs that work together to protect your body) and in children (age 6 months to 17 years).
This study will use a collection of insurance claims and state vaccine registry data called HealthVerity. All patient names and other identifying information is removed.
This study will include children who:
* Are 6 months of age to 17 years of age
* Are enrolled for at least 6 months in a row in a health insurance plan that provides data to HealthVerity
* Are enrolled for at least 6 months in a row in a prescription drug insurance plan that provides data to HealthVerity
* Live in the same US state for 6 months in a row
* Live in a US state that requires COVID-19 vaccine reporting and provides all vaccine history data to HealthVerity
* Do not have mismatches in sex and/or year of birth between any of the available datasets
* Do not have records of having had COVID-19 and/or any COVID-19 vaccine in the 90 days before the start of the study
This study will include adults who:
* Are 18 years of age and older
* Are enrolled for at least 12 months in a row in a health insurance plan that provides data to HealthVerity
* Are enrolled for at least 12 months in a row in a prescription drug insurance plan that provides data to HealthVerity
* Have lived in the same US state for at least 12 months
* Live in a US state that requires COVID-19 reporting and provides all vaccine history data to HealthVerity
* Do not have mismatches in sex and/or year of birth between any of the available datasets
* Do not have records of having had COVID-19 and/or any COVID-19 vaccine in the 90 days before the start of the study
This study will use the data that has already been collected, and no treatment or vaccine will be given in the study.
People who match the information above will be followed in the HealthVerity database for up to 6 months following the first day that a new COVID-19 vaccine is available. This information will be reviewed to see if any of the following happen:
* they had a COVID-19 vaccine
* they're diagnosed with COVID-19 in a doctor's office
* they visit the emergency department for COVID-19
* they visit urgent care for COVID-19
* they are hospitalized for COVID-19
The experiences of people who received a COVID-19 vaccine will be compared to the experiences of people who did not receive the vaccine. This will help to understand how well the Pfizer-BioNTech COVID-19 vaccine works at stopping COVID-19.

开始日期2025-04-01

申办/合作机构

Pfizer Inc.

100 项与复必泰相关的临床结果

登录后查看更多信息

100 项与复必泰相关的转化医学

登录后查看更多信息

100 项与复必泰相关的专利（医药）

登录后查看更多信息

8,920

项与复必泰相关的文献（医药）

2025-12-31·Global Public Health

An intersectional analysis of social constraints and agency among sex workers in Tunisia during the COVID-19 pandemic; the community-based qualitative study EPIC-MENA

Article

作者: Adami, Elisa ; Boulahdour, Nassima ; Di Ciaccio, Marion ; Beldi Chouikha, Khawla ; Bourhaba, Othmane ; Torkhani, Sonia ; Nabli, Montassar ; Lorente, Nicolas ; Karkouri, Mehdi ; Castro Avila, Juliana ; Rojas Castro, Daniela

The economic, social and health impacts of the COVID-19 pandemic varied across population groups. This study aimed to provide a comprehensive view of the effects of socioeconomic constraints on sex workers' agency during the COVID-19 pandemic in Tunisia, using the analytical framework of intersectionality. We performed a thematic content analysis of semi-structured interviews conducted with sex workers (n = 19). Results highlighted the heavy burden of socioeconomic constraints on their agency, and specifically on their decision to continue sex work or not during the pandemic. The fact that there were fewer clients during the pandemic led to greater economic precarity, especially among mothers. Furthermore, interviewees - mostly cisgender male sex workers with same-sex practices - reported increased violence and discrimination by clients and the police. Participants also experienced difficulties accessing health care for themselves and for their children, including access to COVID-19 vaccination. This was especially true for women with a low educational level. Finally, sex workers' mental health was also strongly affected by the pandemic. Findings highlights the role of various intersecting socioeconomic conditions and structural vulnerabilities on sex workers' experience of the COVID-19 pandemic in Tunisia, in terms of health and their capacity to negotiate agency.

2025-12-31·Human Vaccines & Immunotherapeutics

Factors affecting the impact of COVID-19 vaccination on post COVID-19 conditions among adults: A systematic literature review

Review

作者: Haridy, Hammam ; McLaughlin, John M. ; Wright, Olivia ; Bogdanenko, Natalija ; Spinardi, Julia R. ; Whittle, Isabelle ; Rudolph, Abby E. ; Kyaw, Moe H. ; Al Akoury, Nadine ; Markus, Kristen

This systematic literature review summarizes the evidence across 56 publications and pre-prints (January 2020-July 2023) with low-risk of bias based on JBI critical appraisal, that report adjusted estimates for the relationship between COVID-19 vaccination and Post-COVID-19 Condition (PCC) by timing of vaccination relative to infection or PCC-onset. Comparisons of adjusted vaccine effectiveness (aVE) against ≥1 PCC (vs. unvaccinated) across study characteristics known to impact PCC burden or VE against other COVID-19 endpoints were possible for 31 studies where vaccination preceded infection. Seventy-seven percent of pre-infection aVE estimates were statistically significant (range: 7%-95%). Statistically significant pre-infection aVE estimates were slightly higher for mRNA (range: 14%-84%) than non-mRNA vaccines (range: 16%-38%) and aVE ranges before and during Omicron overlapped. Our findings suggest that COVID-19 vaccination before SARS-CoV-2 infection reduces the risk of PCC regardless of vaccine type, number of doses received, PCC definition, predominant variant, and severity of acute infections included.

2025-12-31·Journal of Medical Economics

Characterizing the clinical and economic burden of COVID-19 among individuals with immunocompromising conditions in Ontario, Canada – a matched, population-based observational study

Article

作者: Hamilton, Mackenzie A. ; Qian, Christina ; Nam, Austin ; Voss, M. Lauren ; Johnston, Karissa M. ; Tinajero, Maria

AIMSCOVID-19 continues to be associated with substantial burden among immunocompromised patients (IC). This study aimed to describe and compare outcomes during and following COVID-19 hospitalizations among IC and non-IC patients.METHODSPatients hospitalized with COVID-19 (January 2020-March 2023) were identified in Ontario health administrative claims databases. All eligible IC (≥1 of solid organ or stem cell transplant; hematological malignancy; rheumatoid arthritis; multiple sclerosis; or primary immunodeficiency) were matched (1:4) to eligible non-IC. Clinical, resource, and costburden were assessed during and post-hospitalization. Multivariate regression models were used to estimate relative risks (RRi), rates (RRa), and corresponding 95% confidence intervals (CIs), adjusting for neighborhood deprivation, long-term care residency, baseline comorbidities, and COVID-19 vaccination status.RESULTS9,283 IC hospitalized (mean age 68.7 years; 52.1% female) were matched to 37,127 non-IC. During index hospitalization, IC had greater risks of intensive care unit admission (RRi = 1.06 [1.01-1.12]), ventilation (RRi = 1.27 [1.19-1.36]), and all-cause mortality (RRi = 1.34 [1.27-1.41]) compared to non-IC. Within 30-days post-discharge, IC had greater rates of all-cause readmission (RRa = 1.33 [1.26-1.40]), emergency departments admission (RRa = 1.13 [1.08-1.18]), home oxygen use (RRi = 1.35 [1.15-1.58]), and COVID-19-related rehabilitation (RRa = 1.52 [1.22-1.89]), resulting in 21% (16%-25%) and 51% (45%-58%) greater costs in hospital and post-discharge, respectively. All-cause mortality remained approximately 5% higher for IC vs. non-IC at 30- and 60-days post-discharge (p < .001). Resource use remained elevated among IC with 57% (50%-64%) greater costs within 180 days post-discharge.LIMITATIONSUnmeasured confounding remains; hospital prescription data were not available such that treatments for COVID-19 were not captured. Attribution of post-discharge resource use and costs to COVID-19 was subject to greater uncertainty further from the index hospitalization.CONCLUSIONIC experienced more severe COVID-19 hospitalization outcomes compared to non-IC. COVID-mitigating policies and prophylactic treatments are needed to protect immunocompromised populations.

773

项与复必泰相关的新闻（医药）

2025-05-05

·药时代

3718.5亿美元！全球50款最畅销的重磅药物泽布替尼已具上榜实力可排第49名

正文共： 2046字 3图预计阅读时间： 6分钟（图片来源：Pharma Dive）不久前，全球知名媒体Pharma Dive基于2024年年度销售额数据更新了全球Top50重磅药物名单，药时代团队对这份名单进行了较为系统、细致的梳理和有趣的分析。目前里面没有中国公司的产品，本来我们相信，用不了多久，中国公司的产品将榜上有名。可分析之后发现，原来中国公司已经具备上榜的实力了！现在开始逐步分享，希望对广大中国企业和朋友们有点滴参考价值。欢迎批评指正！多谢！销售额合计3718.5亿美元，平均每款74.37亿美元既然上面提到目前排行榜上没有中国药企及其产品，那么就要知道标准是什么，目前的差距有多大。50款重磅药物2024年的年度销售额合计3718.5亿美元，所以平均每款74.37亿美元，中位数59.15亿美元。全球年度销售额排行榜的最高是来自默沙东的新晋药王Keytruda（K药），为294.8亿美元，最低的是来自艾伯维的治疗慢性淋巴细胞白血病的小分子BCL-2抑制剂唯可来（维奈克拉），为25.8亿美元。所以，这份排行榜的门槛就是25.8亿美元。现在，我们基于搜索到的信息来看看中国药企的实力和上榜的可能性。百济神州研发的针对套细胞淋巴瘤（MCL）、慢性淋巴细胞白血病（CLL）等一系列适应症的BTK抑制剂泽布替尼（Zanubrutinib，商品名：Brukinsa）是首个在美国获批的中国抗癌药，凭借优于伊布替尼的疗效数据快速放量。根据2024年百济神州全年业绩公告，其核心产品泽布替尼（商品名百悦泽）的全球销售额为‌26.44亿美元‌（约合人民币188.59亿元），同比增长105%，占公司总营收的69.3%。如果采用26.44亿美元这个数据，那么百济神州的泽布替尼不仅可以上榜，而且可以位居第49名，取代阿斯利康的C5补体蛋白产品舒立瑞，因为后者2024年的销售额是25.9亿美元，这也意味着，艾伯维的唯可来（维奈克拉）将被挤出TOP50排行榜。百济神州的另一款重磅产品，治疗非小细胞肺癌、霍奇金淋巴瘤的PD-1抑制剂替雷利珠单抗（Tislelizumab，商品名：百泽安）通过与诺华合作拓展欧美市场，2024年全球销售额约6.21亿美元。另一款来自中国的PD-1抑制剂则是信达生物的信迪利单抗（Sintilimab，商品名：达伯舒）。信达负责大中华区市场，海外授权礼来共同开发，虽然美国上市受阻，但东南亚市场增长。2024年全球销售额：约5.26亿美元。有实力冲击排行榜的后备军包括：恒瑞医药的PD-1抑制剂卡瑞利珠单抗（Camrelizumab，商品名：艾瑞卡）获批的适应症主要包括肝癌、食管癌，面临的挑战包括国内集采降价压力，海外布局取得新进展很关键。复星医药的复必泰（mRNA新冠疫苗，与BioNTech合作），2024年全球销售额因疫情需求减少较2023年下降，市场主要在中国港澳台及东南亚地区。恒瑞医药的吡咯替尼（Pyrotinib，商品名：艾瑞妮），针对HER2阳性乳腺癌，是中国首个原创HER2靶向药，东南亚市场表现亮眼。康方生物的卡度尼利单抗（PD-1/CTLA-4双抗，AK104），作为全球首个PD-1/CTLA-4双抗，定价优势显著。信达生物的PCSK9抑制剂信必乐（IBI306），中国首个自主研发的PCSK9抑制剂，2023年8月获批上市，主打适应症高胆固醇血症，定价更低（年治疗费用约2万元人民币，仅为进口药的1/3）。中国新药全球化的挑战与机遇“不出海，就出局。要上榜，先出海！”现在，中国制药界已经达成以上共识。中国创新药全球化面临专利布局、市场竞争和政策环境的多重考验，加速海外临床和商业化进程仍是关键挑战；在PD-1、GLP-1、ADC、TCE等拥挤赛道中，差异化布局成为突破口。国内集采政策倒逼药企转向创新与国际化，而欧美市场之外其它国家和地区的准入则是下一步发展的核心。药时代将持续跟踪报道，欢迎广大朋友们关注、批评指正！参考资料：Pharma Dive官网38笔！596亿美元！跨国药企2025年重磅交易达成，中国公司贡献很大关税阴云下，大型药企并购热情不减，哪些中国药企可能被收购？2024年制药行业并购TOP1028.4亿美元！4月中国创新药出海汇总其它公开资料图片来源：微信订阅号AI38笔！596亿美元！跨国药企2025年重磅交易达成，中国公司贡献很大2025-05-02【直击现场】「星起点」宣讲会直播：50万资金+专家辅导，寻找下一个代谢病创新药突破者！2025-04-30百济神州索托克拉冲刺上市，引领BCL2抑制剂新纪元！2025-04-30版权声明/免责声明本文为原创文章。本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。如有任何问题，请与我们联系。衷心感谢!药时代官方网站:www.drugtimes.cn联系方式:电话:13651980212微信:27674131邮箱:contact@drugtimes.cn点击这里，查看更多精彩!

财报上市批准医药出海

2025-05-01

·生物制品圈

肯尼迪搅局疫苗议题，美疫苗争议再升级

在疫苗问题本就争议不断的美国，卫生与公众服务部部长小罗伯特・F・肯尼迪（Robert F. Kennedy Jr. ，简称 RFK Jr.）的一系列举动，让这一话题变得更加敏感复杂，社会分歧也进一步加剧。提议调整疫苗接种计划，引发争议据 Politico 报道，小罗伯特・F・肯尼迪正考虑将新冠疫苗从美国疾病控制与预防中心（CDC）制定的儿童疫苗接种计划中移除。这一传言若成真，将推翻 CDC 和一众独立顾问三年前做出的建议，被认为是肯尼迪在改变美国疫苗接种实践方面迈出的重要一步。然而，实际情况需全面看待。目前，尚无新冠疫苗获得 FDA 对幼儿的完全批准，辉瑞 / BioNTech 的 Comirnaty 和 Moderna 的 Spikevax 是通过紧急使用授权在 2021 年和 2022 年逐步获批用于低年龄段人群的，且随着 2023 年 5 月 5 日世界卫生组织宣布新冠全球紧急状态结束，情况已有所变化。此外，美国是少数建议健康儿童接种新冠疫苗的国家，英国、澳大利亚等许多国家遵循 WHO 建议，仅对有合并症的儿童和青少年接种。并且，CDC 的免疫实践咨询委员会（ACIP）在 4 月 15 - 16 日的会议上已讨论了调整新冠疫苗建议，可能从普遍加强接种转向基于风险的接种建议。若肯尼迪在 ACIP 6 月投票后再行动，这一举措或许只是顺应常规决策流程。疫苗怀疑论引发信任危机但问题在于，小罗伯特・F・肯尼迪长期以来都表现出对疫苗的怀疑态度。在任职前后，他多次传播关于疫苗安全性和有效性的无端谣言，尽管在确认听证会上他曾向国会保证自己并非反疫苗人士。他对麻疹疫苗的安全性提出质疑，而麻疹疫苗经过数十年验证，曾助力美国在 21 世纪初消除麻疹，后因疫苗接种率下降麻疹才再次出现。他还对得克萨斯州两名未接种疫苗儿童的死亡轻描淡写，给出错误信息。此外，他投入大量政府资源寻找自闭症病因，似乎在支持疫苗与自闭症存在关联这一已被多次驳斥的观点。作为美国卫生部门负责人，他这些误导性和不科学的言论，加深了新冠疫情在美国民众中引发的对疫苗的分歧。反疫苗运动因此得到政府高层支持，而许多支持疫苗的人在讨论儿童新冠疫苗有限数据时，要么选择沉默，要么走向极端，使得原本就复杂的疫苗议题更加难以理性探讨。决策程序受关注，行业前景添变数小罗伯特・F・肯尼迪对疫苗决策过程的潜在影响也备受关注。他有可能在 ACIP 6 月投票前做出改变，或在委员会维持普遍接种建议时反对该决定。由于 CDC 代理主任尚未得到参议院确认，他可能介入决策。此外，他甚至可能完全撤销儿童新冠疫苗的紧急使用授权。这些潜在行动不仅违背他在确认听证会上做出的在现有疫苗审批和安全框架内行事的承诺，还会增加疫苗政策的不确定性，让行业对未来发展充满担忧。从经济角度看，儿童新冠疫苗接种率本就较低，调整接种计划对 Moderna 和辉瑞 / BioNTech 的财务影响或许有限，但这一改变的实施方式以及对整个疫苗行业未来走向的影响不容小觑。疫苗研发生产投入大、需规模效应，若大型企业因此退缩，流感疫苗、麻腮风疫苗、HPV 疫苗等的供应和研发都可能受到影响。当下，FDA 和其他公共卫生机构受小罗伯特・F・肯尼迪政治影响的风险切实存在。在报道这类充满政治争议的话题时，媒体需要力求准确、平衡，以促进公众进行诚实对话。在疫苗问题上，社会急需打破沉默与极端态度，展开理性讨论，否则各方都将深受其害，而目前美国社会似乎还未找到正确的方向。参考来源：https://www.biospace.com/policy/rfk-jr-is-driving-a-wedge-into-already-polarized-vaccine-conversations识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观不本站。

疫苗紧急使用授权

2025-04-30

·药时空

都柏林圣三一学院：辉瑞新冠疫苗BNT162b2或可有效缓解炎症

mRNA疫苗的核心机制是通过递送编码病原体抗原的 mRNA 到宿主细胞中，激活适应性免疫反应。而适应性免疫的激活往往依赖于先天免疫系统的支持。来自辉瑞/BioNTech的BNT162b2 mRNA 疫苗已被证明对重症 COVID-19 及相关死亡病例具有高效性。然其对先天免疫功能的影响迄今为止尚未得到充分了解。近年来的研究表明，先天免疫细胞可以通过 “训练免疫”（trained immunity）获得长期的免疫记忆，从而在后续感染中更有效地发挥作用。然而，过度炎症可能导致严重 SARS-CoV-2 感染以及许多其他免疫介导疾病。2025年4月28日，都柏林圣三一学院研究团队在期刊Clinical Immunology在线发表了题为“BNT162b2 mRNA vaccination attenuates innate immune function in humans”的研究论文，首次发现BNT162b2 新冠疫苗不仅靶向新冠病毒，还可通过重编程先天免疫细胞调节炎症，减少了与疫苗靶点无关的其他细菌、真菌或病毒感染产生的促炎介质。本次研究对象为八名健康志愿者，他们在接种 BNT162b2 mRNA 新冠疫苗前献血，并在首次接种后第 14 天和第 28 天再次献血。蛋白质组学蛋白质组学分析表明，接种疫苗后第 14 天和第 28 天，炎症标志物如TRIM21、CCL17、DFFA等显著下调。这一结果表明，疫苗接种可能诱导了某种形式的免疫耐受，减少了炎症反应。细胞因子尽管血浆中炎症反应的核心细胞因子如 TNF 和 IL-6 等的浓度在接种后未发生显著变化，但在体外刺激条件下，外周血单核细胞（PBMC）的细胞因子分泌模式发生了显著改变。首先，在接种14天后，PBMC强烈响应病菌来源的刺激，如LPS （革兰氏阴性菌细胞壁脂多糖，先天免疫系统识别受体的激动剂）、金黄色葡萄球菌肠毒素 B（SEB）以及SARS-CoV-2 刺突抗原等，TNF和IL-6的表达均有上调。这些结果，证明疫苗成功激活了先天免疫反应。但接下来，随着免疫系统的重新调整，相应细胞因子在第28天显著下调，表明在疫苗接种后的较晚阶段，PBMC从早期的激活状态逐渐过渡到更稳定的免疫记忆状态。此外，使用其他刺激物（如 TLR2 激动剂 Pam3Cysk4、TLR4 激动剂 LPS、热灭活的结核分枝杆菌（M.tb）和白色念珠菌（Candida albicans））激活PBMC的结果显示，接种后第 14 天，PBMC的 TNF 和 IL-6 分泌便已经有显著降低。这再次证明PBMC对非特异性刺激的响应能力在接种后受到抑制。图：接种疫苗后，炎症的循环生物标志物下调总结与展望Sarah Connolly 是圣詹姆斯医院 Basdeo 实验室的博士生，她在爱尔兰研究中心的资助下开展了这项研究，她表示：“我们的研究结果强调了探索初始启动后疫苗接种的先天免疫反应的重要性。这项研究证实，mRNA疫苗可以改变对相关和不相关病原体的先天免疫反应。这项研究意义重大，因为它将揭示疫苗接种更广泛的免疫学效应，以及如何利用它优化疫苗设计和接种计划。”圣詹姆斯医院三一转化医学研究所人类与转化免疫学组首席研究员、资深作者 Sharee Basdeo 博士补充道：“由于 mRNA 疫苗平台是全新并非常成功的方向，这项研究提高了我们对其对先天免疫的非特异性影响的理解，这将有助于为大流行防范提供信息，并帮助了解该平台预防其他传染病或调节炎症的能力。”参考资料Connolly, Sarah A et al. “BNT162b2 mRNA vaccination attenuates innate immune function in humans.” Clinical immunology (Orlando, Fla.), vol. 276 110488. 25 Mar. 2025, doi:10.1016/j.clim.2025.110488识别微信二维码，可添加药时空小编请注明：姓名+研究方向！

疫苗信使RNA临床研究临床结果

100 项与复必泰相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11971	复必泰	J07BX	DB15696

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
新型冠状病毒感染	沙特阿拉伯	-	-
新型冠状病毒感染	巴林	-	-
新型冠状病毒感染	墨西哥	-	-

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
严重急性呼吸综合征	临床3期	巴西	Pfizer Inc.	2021-02-16
严重急性呼吸综合征	临床3期	美国	BioNTech SE	2021-02-16
严重急性呼吸综合征	临床3期	西班牙	BioNTech SE	2021-02-16
严重急性呼吸综合征	临床3期	美国	Pfizer Inc.	2021-02-16
严重急性呼吸综合征	临床3期	巴西	BioNTech SE	2021-02-16
严重急性呼吸综合征	临床3期	西班牙	Pfizer Inc.	2021-02-16
严重急性呼吸综合征	临床前	南非	BioNTech SE	2021-02-16
严重急性呼吸综合征	临床前	英国	Pfizer Inc.	2021-02-16
严重急性呼吸综合征	临床前	南非	Pfizer Inc.	2021-02-16
严重急性呼吸综合征	临床前	英国	BioNTech SE	2021-02-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05886777 (CTgov)	临床2期	新型冠状病毒感染 \| 肺部感染	1,142	QIV+RSVpreF (Group 1: [RSVpreF + BNT162b2] + QIV)	膚窪製窪糧憲糧繭壓範(廠鬱夢鹽醖獵願壓鹽獵) = 糧憲鏇範網範範鹹獵鬱鹽廠簾簾網顧願願願遞 (餘遞淵構築鹹齋衊鏇網, 繭網鑰製襯選簾艱齋網 ~ 鏇網製獵淵憲鹽積鹹糧) 更多	-	2024-12-18
				Placebo+BNT162b2+RSVpreF (Group 2: [RSVpreF+BNT162b2] + Placebo)	膚窪製窪糧憲糧繭壓範(廠鬱夢鹽醖獵願壓鹽獵) = 淵艱夢構壓範構鹹獵糧鹽廠簾簾網顧願願願遞 (餘遞淵構築鹹齋衊鏇網, 選製餘願壓構憲廠齋夢 ~ 積積廠網範簾膚夢餘膚) 更多
NCT05228730 (MIACoV, CTgov)	临床3期	新型冠状病毒感染	13	Tozinameran (Standard Pfizer-BioNTech Booster Group)	齋簾範衊鑰築糧淵簾簾(獵繭鹽齋憲鏇憲積簾觸) = 遞網鑰範構鏇網網窪遞廠簾衊構觸鬱齋醖簾鹽 (繭壓顧顧鬱積夢鑰淵醖, 願膚衊積簾廠襯鏇艱衊 ~ 願遞築簾獵齋鬱鏇壓鹽) 更多	-	2024-12-16
				Tozinameran - fractional dose (Fractional Pfizer-BioNTech Booster Group)	齋簾範衊鑰築糧淵簾簾(獵繭鹽齋憲鏇憲積簾觸) = 構窪選憲糧製範鑰襯簾廠簾衊構觸鬱齋醖簾鹽 (繭壓顧顧鬱積夢鑰淵醖, 積顧糧構願餘窪淵選糧 ~ 壓餘廠觸壓齋夢餘製襯) 更多
NCT04949490 (CTgov)	临床2期	新型冠状病毒感染	137	BNT162b2 (Comirnaty)+BNT162 (Group A Comirnaty)	蓋網鹹簾膚餘鹽醖繭憲(簾鹽鹹艱窪鹹簾蓋構鏇) = 淵艱廠襯顧醖繭製繭繭廠範齋齋網鹽鬱醖淵顧 (艱膚築積網網願築膚鑰, 齋窪構遞蓋衊廠窪窪製 ~ 淵壓壓夢獵鹽製顧築積) 更多	-	2024-09-19
				BNT162b2s01 (Group A BNT162b2s01)	蓋網鹹簾膚餘鹽醖繭憲(簾鹽鹹艱窪鹹簾蓋構鏇) = 製築廠鏇繭鹽遞衊醖淵廠範齋齋網鹽鬱醖淵顧 (艱膚築積網網願築膚鑰, 願窪醖衊製構餘顧構壓 ~ 餘膚夢鹹築繭憲遞窪願) 更多
EULAR2024	N/A	风湿性疾病	118	COVID-19 VACCINATION (Vaccinated Group)	鏇餘積顧憲淵鏇積醖餘(淵製齋鑰鹽網衊繭繭構) = 憲窪鹹窪膚製範構簾夢製襯蓋網積範齋鹽壓夢 (構鬱餘鹽繭廠餘廠觸鏇 ) 更多	积极	2024-06-05
				COVID-19 VACCINATION (Hesitancy Group)	艱繭齋範鏇夢鏇鑰鹹簾(製範願襯廠鏇繭壓窪膚) = 遞衊鑰齋構範襯襯積艱憲積鏇糧築鹽觸衊遞簾 (艱製製壓襯壓繭壓齋範 )
NCT04792567 (AMA-VACC, CTgov)	临床4期	继发进展型多发性硬化	41	BAF312+BNT162+mRNA-1273 (Siponimod - Continuous)	獵艱憲糧廠憲選觸鹽齋(餘壓糧淵遞簾淵艱糧觸) = 築鹽淵鹹獵鹹遞餘鏇夢願艱糧衊鹽廠鏇窪網鑰 (製蓋膚獵蓋製獵鹽願壓, 齋鬱齋構構蓋艱築遞襯 ~ 觸獵齋憲鏇繭醖餘繭繭) 更多	-	2024-05-17
				BAF312+BNT162+mRNA-1273 (Siponimod- Interrupted)	獵艱憲糧廠憲選觸鹽齋(餘壓糧淵遞簾淵艱糧觸) = 糧鹽範艱鏇窪憲遞鬱獵願艱糧衊鹽廠鏇窪網鑰 (製蓋膚獵蓋製獵鹽願壓, 淵繭鹹鑰網範淵製範築 ~ 構夢糧獵繭選醖製遞襯) 更多
NEWS 人工标引	N/A	新型冠状病毒感染	250,000	BNT162b2	(繭願築願遞齋繭艱夢鏇) = 鬱鬱鬱築憲鹹獵糧鏇艱簾鬱積淵簾鹽鬱鏇願繭 (醖膚壓淵淵範鑰糧艱網 )	积极	2024-01-08
				unvaccinated	-
NCT04969601 (PACIFIC, ASH2023)	临床1/2期	急性白血病	76	BNT162b2 Vaccine (Children with acute leukemia)	鏇積鹹網憲築夢壓網鹹(觸簾鏇築襯網夢築積糧) = 構壓憲蓋觸壓鹹壓糧淵蓋齋獵築蓋窪鏇積壓襯 (網鹽鬱鏇顧衊壓膚遞繭 ) 更多	-	2023-12-11
				BNT162b2 Vaccine (Siblings)	鏇積鹹網憲築夢壓網鹹(觸簾鏇築襯網夢築積糧) = 積觸構選獵窪觸製齋願蓋齋獵築蓋窪鏇積壓襯 (網鹽鬱鏇顧衊壓膚遞繭 ) 更多
NCT05310084 (CTgov)	临床3期	新型冠状病毒感染 \| 流感病毒感染	1,134	Placebo+BNT162b2+Seasonal Inactivated Influenza Vaccine (Coadministration Group)	鏇糧齋觸願齋網糧獵鑰(襯鏇鏇繭襯選觸構襯選) = 選窪齋繭鹽構艱衊簾網壓選窪選願鏇構獵艱選 (鹹選鏇顧憲鏇鹽鹽糧遞, 蓋醖餘選選鑰淵簾積選 ~ 襯糧襯範廠壓壓鹽糧構) 更多	-	2023-11-24
				Placebo+BNT162b2+Seasonal Inactivated Influenza Vaccine (Separate Administration Group)	鏇糧齋觸願齋網糧獵鑰(襯鏇鏇繭襯選觸構襯選) = 構夢顧夢製選窪膚繭壓壓選窪選願鏇構獵艱選 (鹹選鏇顧憲鏇鹽鹽糧遞, 鑰網觸願艱觸製壓鑰窪 ~ 積蓋夢憲憲積蓋網鑰範) 更多
NCT05596734 (Corporate Publications) 人工标引	临床1/2期	新型冠状病毒感染	-	Omicron BA.4/BA.5	(鹹願鹹窪衊壓獵願積構) = Lead formulations evaluated in the Phase 1/2 study demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains 艱鹽積顧窪觸膚鬱鏇選 (築壓齋鏇餘範鏇顧鏇遞 ) 更多	积极	2023-10-26
NCT04977479 (CTgov)	临床2期	新型冠状病毒感染 \| 超敏反应	20	Placebo+Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) (Blinded Active Vaccine 2)	選衊醖遞簾鑰願選糧製(憲築蓋觸鹹顧範鏇鹽醖) = 觸壓積醖鹽廠簾蓋膚願膚艱齋廠觸衊壓鏇夢廠 (醖構範壓齋壓製艱製觸, 構壓願構遞獵製鑰淵膚 ~ 糧醖觸網壓廠觸製糧膚) 更多	-	2023-10-16
				Pfizer-BioNTech COVID-19 Vaccine, Bivalent+Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) (Open-Label Booster Vaccine)	醖襯獵憲鏇膚憲廠遞襯(壓鏇鹹艱網淵壓繭鬱網) = 鹹簾獵淵顧網廠鬱鏇窪廠鏇繭繭選積網製網構 (膚範觸選齋廠糧遞夢鏇, 艱醖艱積獵鹽獵醖廠鹹 ~ 鹹壓夢膚夢築範構築糧) 更多